Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/FKBP5_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/FKBP5_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FKBP5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FKBP5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/FKBP5_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FKBP5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FKBP5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FKBP5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FKBP5_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FKBP5_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FKBP5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00182088 | Oral cavity | OSCC | peptidyl-proline modification | 42/7305 | 58/18723 | 2.49e-07 | 3.92e-06 | 42 |
GO:00004134 | Oral cavity | OSCC | protein peptidyl-prolyl isomerization | 28/7305 | 42/18723 | 2.61e-04 | 1.67e-03 | 28 |
GO:000645725 | Oral cavity | EOLP | protein folding | 59/2218 | 212/18723 | 1.76e-10 | 1.79e-08 | 59 |
GO:006107724 | Oral cavity | EOLP | chaperone-mediated protein folding | 28/2218 | 67/18723 | 5.43e-10 | 4.31e-08 | 28 |
GO:000645716 | Prostate | BPH | protein folding | 85/3107 | 212/18723 | 2.37e-16 | 4.74e-14 | 85 |
GO:006107716 | Prostate | BPH | chaperone-mediated protein folding | 30/3107 | 67/18723 | 5.88e-08 | 1.57e-06 | 30 |
GO:00182087 | Prostate | BPH | peptidyl-proline modification | 18/3107 | 58/18723 | 4.75e-03 | 2.27e-02 | 18 |
GO:000645717 | Prostate | Tumor | protein folding | 85/3246 | 212/18723 | 3.37e-15 | 5.37e-13 | 85 |
GO:006107717 | Prostate | Tumor | chaperone-mediated protein folding | 30/3246 | 67/18723 | 1.60e-07 | 4.02e-06 | 30 |
GO:001820814 | Prostate | Tumor | peptidyl-proline modification | 18/3246 | 58/18723 | 7.57e-03 | 3.37e-02 | 18 |
GO:000645726 | Skin | AK | protein folding | 44/1910 | 212/18723 | 3.54e-06 | 8.91e-05 | 44 |
GO:006107725 | Skin | AK | chaperone-mediated protein folding | 20/1910 | 67/18723 | 6.97e-06 | 1.55e-04 | 20 |
GO:0006457111 | Skin | cSCC | protein folding | 131/4864 | 212/18723 | 2.96e-28 | 1.32e-25 | 131 |
GO:0061077111 | Skin | cSCC | chaperone-mediated protein folding | 46/4864 | 67/18723 | 2.93e-13 | 1.75e-11 | 46 |
GO:001820810 | Skin | cSCC | peptidyl-proline modification | 37/4864 | 58/18723 | 1.53e-09 | 5.82e-08 | 37 |
GO:00004136 | Skin | cSCC | protein peptidyl-prolyl isomerization | 26/4864 | 42/18723 | 9.92e-07 | 1.78e-05 | 26 |
GO:0006457112 | Thyroid | PTC | protein folding | 137/5968 | 212/18723 | 8.29e-23 | 2.01e-20 | 137 |
GO:001820817 | Thyroid | PTC | peptidyl-proline modification | 42/5968 | 58/18723 | 2.71e-10 | 8.91e-09 | 42 |
GO:0061077112 | Thyroid | PTC | chaperone-mediated protein folding | 46/5968 | 67/18723 | 6.91e-10 | 2.08e-08 | 46 |
GO:00004137 | Thyroid | PTC | protein peptidyl-prolyl isomerization | 30/5968 | 42/18723 | 1.65e-07 | 3.13e-06 | 30 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0491523 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
hsa0491533 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
hsa0491542 | Breast | DCIS | Estrogen signaling pathway | 35/846 | 138/8465 | 1.40e-07 | 2.51e-06 | 1.85e-06 | 35 |
hsa0491552 | Breast | DCIS | Estrogen signaling pathway | 35/846 | 138/8465 | 1.40e-07 | 2.51e-06 | 1.85e-06 | 35 |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa04915110 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0491543 | Cervix | N_HPV | Estrogen signaling pathway | 16/349 | 138/8465 | 1.68e-04 | 1.53e-03 | 1.19e-03 | 16 |
hsa0491553 | Cervix | N_HPV | Estrogen signaling pathway | 16/349 | 138/8465 | 1.68e-04 | 1.53e-03 | 1.19e-03 | 16 |
hsa04915 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049151 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049152 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049153 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049154 | Colorectum | CRC | Estrogen signaling pathway | 29/1091 | 138/8465 | 4.83e-03 | 2.66e-02 | 1.80e-02 | 29 |
hsa049155 | Colorectum | CRC | Estrogen signaling pathway | 29/1091 | 138/8465 | 4.83e-03 | 2.66e-02 | 1.80e-02 | 29 |
hsa0491525 | Endometrium | AEH | Estrogen signaling pathway | 35/1197 | 138/8465 | 3.10e-04 | 2.40e-03 | 1.75e-03 | 35 |
hsa04915111 | Endometrium | AEH | Estrogen signaling pathway | 35/1197 | 138/8465 | 3.10e-04 | 2.40e-03 | 1.75e-03 | 35 |
hsa0491514 | Liver | Cyst | Estrogen signaling pathway | 16/339 | 138/8465 | 1.20e-04 | 1.57e-03 | 1.30e-03 | 16 |
hsa0491515 | Liver | Cyst | Estrogen signaling pathway | 16/339 | 138/8465 | 1.20e-04 | 1.57e-03 | 1.30e-03 | 16 |
hsa0491529 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
hsa04915113 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FKBP5 | SNV | Missense_Mutation | | c.1303G>C | p.Glu435Gln | p.E435Q | Q13451 | protein_coding | tolerated(0.11) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FKBP5 | SNV | Missense_Mutation | | c.728N>G | p.Tyr243Cys | p.Y243C | Q13451 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FKBP5 | SNV | Missense_Mutation | novel | c.1142A>G | p.Asn381Ser | p.N381S | Q13451 | protein_coding | tolerated(0.34) | possibly_damaging(0.685) | TCGA-B6-A402-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PD |
FKBP5 | insertion | Nonsense_Mutation | novel | c.24_25insTTAACCTCTCTGTGATTAAGTTCCTGTTTGTAAAATTAGAATAAT | p.Lys8_Asn9insLeuThrSerLeuTerLeuSerSerCysLeuTerAsnTerAsnAsn | p.K8_N9insLTSL*LSSCL*N*NN | Q13451 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FKBP5 | SNV | Missense_Mutation | rs200334349 | c.119T>C | p.Val40Ala | p.V40A | Q13451 | protein_coding | tolerated(0.34) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FKBP5 | SNV | Missense_Mutation | | c.391G>C | p.Glu131Gln | p.E131Q | Q13451 | protein_coding | tolerated(0.06) | possibly_damaging(0.55) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
FKBP5 | SNV | Missense_Mutation | rs759431987 | c.1216N>T | p.Arg406Cys | p.R406C | Q13451 | protein_coding | deleterious(0) | possibly_damaging(0.74) | TCGA-MA-AA3Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FKBP5 | SNV | Missense_Mutation | | c.346N>A | p.Ala116Thr | p.A116T | Q13451 | protein_coding | tolerated(0.15) | benign(0.003) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
FKBP5 | SNV | Missense_Mutation | novel | c.366N>G | p.Ile122Met | p.I122M | Q13451 | protein_coding | deleterious(0) | possibly_damaging(0.904) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FKBP5 | SNV | Missense_Mutation | novel | c.695A>C | p.Lys232Thr | p.K232T | Q13451 | protein_coding | deleterious(0.04) | benign(0.081) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2289 | FKBP5 | DRUGGABLE GENOME | | escitalopram | ESCITALOPRAM | |
2289 | FKBP5 | DRUGGABLE GENOME | | gemcitabine | GEMCITABINE | 23936393 |
2289 | FKBP5 | DRUGGABLE GENOME | | citalopram | CITALOPRAM | 18597649,21449676,20709156,19676097,15565110,23733030,17467808 |
2289 | FKBP5 | DRUGGABLE GENOME | | clozapine | CLOZAPINE | 25751398 |
2289 | FKBP5 | DRUGGABLE GENOME | | paroxetine | PAROXETINE | 18597649,21449676,20709156,19676097,15565110,23733030,17467808 |
2289 | FKBP5 | DRUGGABLE GENOME | | corticosteroids | | 21788965 |
2289 | FKBP5 | DRUGGABLE GENOME | | fluoxetine | FLUOXETINE | 20709156,15565110 |
2289 | FKBP5 | DRUGGABLE GENOME | | bupropion | BUPROPION | 22947179 |
2289 | FKBP5 | DRUGGABLE GENOME | | nefazodone | NEFAZODONE | 18597649,21449676,20709156,19676097,15565110,23733030,17467808 |
2289 | FKBP5 | DRUGGABLE GENOME | | antidepressants | | 18597649,21449676,20709156,19676097,15565110,23733030,17467808 |